Table 1.
Leptin and VEGF enhance ES formation by HUVEC.
| Conditions | ES (%) |
|---|---|
| Untreated | 100.0 |
| Leptin | 178.0 ± 3.0 |
| Leptin + Aca1 10 nM | 90.0 ± 1.0 |
| Leptin + Aca1 25 nM | 79.0 ± 6.5 |
| Leptin + Aca1 50 nM | 72.0 ± 32.5 |
| Aca1 10 nM | 103.5 ± 12.0 |
| Aca1 25 nM | 90.0 ± 1.0 |
| Aca1 50 nM | 68.0 ± 4.0 |
| VEGF | 160.0 ± 13.0 |
| VEGF + SU1498 1 μM | 121.0 ± 30.0 |
| VEGF + SU1498 5 μM | 98.0 ± 14.5 |
| VEGF + SU1498 10 μM | 73.0 ± 6.0 |
| SU1498 1 μM | 100.5 ± 23.0 |
| SU1498 5 μM | 91.0 ± 1.4 |
| SU1498 10 μM | 60.0 ± 10.0 |
ObR and VEGFR inhibitors counteract this effect.
Number of ES after treatment with 100 ng/mL leptin and/or Aca1Free 10, 25 and 50 nM or with 50 ng/mL VEGF and/or SU1498 1, 5 and 10 μM was scored as described in Materials and Methods. Untreated cells were taken as control (100%). Tube-like formation assay was performed for 8 h in VCBM. Means ± SD are shown.